Humacyte, Inc.
HUMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.01 | -0.01 | 0.14 |
| FCF Yield | -8.70% | -8.31% | -12.82% | -4.45% |
| EV / EBITDA | -21.93 | -11.15 | 4.04 | -34.28 |
| Quality | ||||
| ROIC | -35.55% | -24.18% | -15.93% | -23.24% |
| Gross Margin | 65.47% | -588.70% | -282.79% | 50.00% |
| Cash Conversion Ratio | 1.37 | 0.70 | -0.73 | 1.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,064,382.02% | 537.88% | 79.82% | 66.53% |
| Free Cash Flow Growth | 11.22% | 6.41% | -8.22% | -11.74% |
| Safety | ||||
| Net Debt / EBITDA | -0.79 | -1.38 | -1.07 | 1.71 |
| Interest Coverage | -9.34 | -11.68 | -7.73 | -11.20 |
| Efficiency | ||||
| Inventory Turnover | 0.01 | 0.19 | 0.25 | 0.00 |
| Cash Conversion Cycle | 3,189.88 | 310.48 | 196.28 | -111.82 |